Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
Holding DE:4AB?
Track your performance easily
4AB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€139.50 - €192.50
Previous Close€170.04
Volume1.16K
Average Volume (3M)2.38K
Market Cap
€299.06B
Enterprise Value€360.37B
Total Cash (Recent Filing)$7.29B
Total Debt (Recent Filing)$71.08B
Price to Earnings (P/E)64.4
Beta-0.03
Next Earnings
Jan 29, 2025EPS Estimate
€2.86Next Dividend Ex-Date
Jan 15, 2025Dividend Yield3.48%
Share Statistics
EPS (TTM)2.64
Shares Outstanding1,767,140,323
10 Day Avg. Volume1,672
30 Day Avg. Volume2,383
Standard Deviation0.07
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)49.87
Price to Sales (P/S)5.66
Price to Cash Flow (P/CF)14.40
P/FCF Ratio13.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.49
Enterprise Value/Gross Profit10.63
Enterprise Value/Ebitda19.80
Forecast
1Y Price Target
€194.73Price Target Upside14.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
AbbVie News
Bulls Say, Bears Say
Bulls Say
Market PositionABBV is a dominant player in the global aesthetics market.
New Product GrowthPost Humira growth recovery is now at hand, powered by newer products, and unencumbered by patent expirations.
Product MomentumMomentum for Skyrizi and Rinvoq remains strong with significant year-over-year growth in the US market, demonstrating robust demand.
Bears Say
Acquisition And Asset Write-downThe company overpaid for Cerevel and will likely have to take a significant emraclidine write-down in early 2025.
Drug Development And TrialsAbbvie's Emraclidine failed to meet primary endpoints in two Phase 2 schizophrenia trials, leading to its removal from the ABBV model.
Financial PerformanceManagement lowered 2024 aesthetics guidance to $5.3 billion from $5.5 billion, which includes a reduction in Juvederm sales.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
21.85% Mutual Funds
15.25% Other Institutional Investors
41.41% Public Companies and
Individual Investors
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €139.50 and its highest was €192.50 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jan 29, 2025 which is in 29 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Oct 30, 2024. The company reported €2.881 earnings per share for the quarter, beating the consensus estimate of €2.805 by €0.077.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.572 which represents an annual dividend yield of 3.48%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is €2.86.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,140,400 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.881 in its last earnings report, beating expectations of €2.805. Following the earnings report the stock price went up 4.067%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 260M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€194.73 (14.52% Upside)
€194.73 (14.52% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 94%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $310.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.85%
12-Months-Change
Fundamentals
Return on Equity
56.06%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
4AB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie demonstrated strong commercial, operational, and R&D execution with significant growth from its ex-HUMIRA platform, increased revenue and EPS guidance, and successful acquisition and integration of Cerevel Therapeutics. However, challenges remain with declining HUMIRA sales, aesthetic market headwinds, and competitive pressures on IMBRUVICA.Read More>---
4AB Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
4AB Stock 12 Month Forecast
Average Price Target
€194.73
▲(14.52% Upside)
Technical Analysis
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
35/40 ratings generated profit
1 Year Average Return
+20.95%
reiterated a buy rating 15 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +20.95% per trade.
---